Astec Lifesciences Ltd
ASTECAstec Lifesciences Ltd
ASTEC
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -20.12 | 5.64 | 0.14% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 29.46 | 3.34 | 1.38% |
Forecast & Ratings
Detailed Forecast from 1 analyst
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Astec LifeSciences Limited is a holding company. The Company is a producer of agrochemicals and pharmaceutical intermediates.
Peers
Compare with peersFertilisers And Chemicals Travancore Ltd
Coromandel International Ltd
UPL Ltd
Bayer Cropscience Ltd
Chambal Fertilisers and Chemicals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ cr.
All values in ₹ cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 240.19 | 301.53 | 395.02 | 442.06 | 534.54 | 562.79 | 687.04 | 641.23 | 463.82 | 378.34 | ||||||||||
Raw Materials | 160.59 | 179.66 | 224.22 | 295.05 | 333.81 | 344.60 | 444.82 | 460.83 | 318.82 | 444.08 | ||||||||||
| Power & Fuel Cost | 13.84 | 15.75 | 17.87 | 23.80 | 28.80 | 25.28 | 38.04 | 45.68 | 35.87 | |||||||||||
| Employee Cost | 15.89 | 20.38 | 21.71 | 25.10 | 29.92 | 38.35 | 50.31 | 52.26 | 61.74 | |||||||||||
| Selling & Administrative Expenses | 15.62 | 13.65 | 16.74 | 15.41 | 21.83 | 17.17 | 23.55 | 25.77 | 20.97 | |||||||||||
| Operating & Other expenses | -1.38 | 17.44 | 33.43 | -4.93 | 23.07 | 17.92 | -34.22 | -32.63 | 26.69 | |||||||||||
EBITDA | 35.63 | 54.65 | 81.05 | 87.63 | 97.11 | 119.47 | 164.54 | 89.32 | -0.27 | -65.74 | ||||||||||
| Depreciation/Amortization | 10.40 | 13.68 | 14.68 | 19.35 | 23.16 | 25.66 | 34.36 | 33.65 | 36.25 | 38.45 | ||||||||||
| PBIT | 25.23 | 40.97 | 66.37 | 68.28 | 73.95 | 93.81 | 130.18 | 55.67 | -36.52 | -104.19 | ||||||||||
| Interest & Other Items | 12.81 | 12.24 | 10.66 | 12.38 | 12.59 | 4.75 | 9.06 | 20.71 | 25.23 | 29.13 | ||||||||||
| PBT | 12.42 | 28.73 | 55.71 | 55.90 | 61.36 | 89.06 | 121.12 | 34.96 | -61.75 | -133.32 | ||||||||||
| Taxes & Other Items | 7.46 | 9.62 | 20.81 | 20.17 | 13.84 | 24.02 | 31.26 | 9.39 | -14.81 | -29.72 | ||||||||||
| Net Income | 4.96 | 19.11 | 34.90 | 35.73 | 47.52 | 65.04 | 89.86 | 25.57 | -46.94 | -103.60 | ||||||||||
| EPS | 2.55 | 9.81 | 17.88 | 18.29 | 24.29 | 33.22 | 45.86 | 13.04 | -23.94 | -52.83 | ||||||||||
| DPS | 0.00 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.15 | 0.08 | 0.08 | 0.06 | 0.05 | 0.03 | 0.11 | — | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
MaterialsFertilizers & Agro Chemicals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Astec Lifesciences Ltd | -44.41 | 5.64 | 0.14% |
| Fertilisers And Chemicals Travancore Ltd | 366.87 | 38.98 | 0.12% |
| Coromandel International Ltd | 32.41 | 5.63 | 0.33% |
| UPL Ltd | -35.43 | 1.30 | 0.18% |
Price Comparison
Compare ASTEC with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Astec Lifesciences Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
Nippon India Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 2.4429% | Percentage of the fund’s portfolio invested in the stock 0.08% | Change in the portfolio weight of the stock over the last 3 months -0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 112/232 (-4) |
TATA ASSET MANAGEMENT LTD#TATA MF-TATA RETIREMENT SAVINGS FUND-PROGRESSIVE-DIRECT PLAN-GROWTH Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.9065% | Percentage of the fund’s portfolio invested in the stock 0.90% | Change in the portfolio weight of the stock over the last 3 months -0.09% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 24/68 (-2) |
ICICI Prudential Commodities Fund - Cumulative - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.5858% | Percentage of the fund’s portfolio invested in the stock 0.50% | Change in the portfolio weight of the stock over the last 3 months -0.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 35/56 (-1) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividend Cuts
ASTEC has increased or maintained dividend levels over the last 5 years
Dividend Yield
Current dividend yield is 0.14%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.41 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJul 21, 2023
Dividend/Share
₹1.50
Ex DateEx Date
Jul 21, 2023
Cash Dividend
Ex DateEx DateJul 19, 2022
Dividend/Share
₹1.50
Ex DateEx Date
Jul 19, 2022
Cash Dividend
Ex DateEx DateJul 22, 2021
Dividend/Share
₹1.50
Ex DateEx Date
Jul 22, 2021
Cash Dividend
Ex DateEx DateJul 16, 2020
Dividend/Share
₹1.50
Ex DateEx Date
Jul 16, 2020
Cash Dividend
Ex DateEx DateJul 18, 2019
Dividend/Share
₹1.50
Ex DateEx Date
Jul 18, 2019
Net Loss of Astec Lifesciences reported to Rs 38.56 crore in the quarter ended September 2024 as against net loss of Rs 13.43 crore during the previous quarter ended September 2023. Sales declined 11.05% to Rs 98.55 crore in the quarter ended September 2024 as against Rs 110.79 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales98.55110.79 -11 OPM %-20.03-3.09 - PBDT-27.07-8.44 -221 PBT-38.54-17.60 -119 NP-38.56-13.43 -187 Powered by Capital Market - Live
Astec Lifesciences will hold a meeting of the Board of Directors of the Company on 25 October 2024Powered by Capital Market - Live
Astec LifeSciences announced that Dr. Brahma Nand Vyas has tendered his resignation as an 'Independent Director' of the Company with effect from closure of business hours on 4 October 2024. Powered by Capital Market - Live
Astec Lifesciences announced that Anurag Roy has tendered his resignation as the 'Whole Time Director & Chief Executive Officer' of the Company with effect from closure of business hours on 25 October 2024.Powered by Capital Market - Live
Astec Lifesciences has appointed Dr. Ganapati Dadasaheb Yadav as a 'Non-Executive & Independent Director' of the Company with effect from 17 September 2024. Powered by Capital Market - Live
Astec Lifesciences reports consolidated net loss of Rs 39.72 crore in the June 2024 quarter
Net Loss of Astec Lifesciences reported to Rs 39.72 crore in the quarter ended June 2024 as against net loss of Rs 8.19 crore during the previous quarter ended June 2023. Sales declined 51.44% to Rs 69.37 crore in the quarter ended June 2024 as against Rs 142.85 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales69.37142.85 -51 OPM %-66.672.19 - PBDT-52.37-1.62 -3133 PBT-61.64-11.01 -460 NP-39.72-8.19 -385 Powered by Capital Market - Live
Astec Lifesciences will hold a meeting of the Board of Directors of the Company on 29 July 2024.Powered by Capital Market - Live
Astec LifeSciences sinks 11% as Q4 earnings take a knock
Astec LifeSciences tumbles 10% on loss in Q4; stock down 44% in six months
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 0.97%, vs industry avg of 10.43%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.34% to 0.22%